February 2022 - Saturn Partners

Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences

Posted on February 25, 2022 at 4:02 pm.

– Acquisition of next-generation Kv7 channel activators for target indications including epilepsy, pain disorders and affective disorders – BHV-7000 is the lead asset from Kv7 channel platform and is potentially a best-in-class potassium channel activator with a profile suggestive for … Continued

Third Pole Therapeutics Closes $25M Financing – eNOfit™ Wearable Device Now Ready for Clinical Trials

Posted on February 3, 2022 at 8:40 am.

Written by saturnadmin

– eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year – Funding will support device optimization and … Continued

Monthly Archives: February 2022